Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Por um escritor misterioso
Descrição
Long-Term Efficacy and Safety of Dupilumab in Adolescents with
Dupilumab May Improve Lung Function in Children Age 6-11 with
Frontiers Severe pediatric asthma therapy: Dupilumab
JCM, Free Full-Text
Dupilumab efficacy in children with uncontrolled, moderate-to
FDA Approves Dupixent® as First Biologic for Treatment of Children
Full article: Dupilumab in the management of moderate-to-severe
FDA Approves Dupilumab for Moderate-to-Severe Asthma
Dupilumab leads to better-controlled asthma and quality of life in
Dupilumab in children aged 6 months to younger than 6 years with
de
por adulto (o preço varia de acordo com o tamanho do grupo)
